Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Kymera Therapeutics (NASDAQ:KYMR) had its target price raised by HC Wainwright from $54.00 to $60.00 in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts have also recently commented on KYMR. UBS Group dropped their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Morgan Stanley increased their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. Guggenheim increased their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Truist Financial reiterated a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $56.69.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $31.35 on Friday. The stock’s fifty day moving average price is $39.02 and its two-hundred day moving average price is $43.74. The company has a market cap of $2.03 billion, a PE ratio of -13.40 and a beta of 2.18. Kymera Therapeutics has a fifty-two week low of $29.16 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, equities analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 15.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Kymera Therapeutics in the 4th quarter worth about $4,610,000. GF Fund Management CO. LTD. bought a new position in shares of Kymera Therapeutics in the 4th quarter worth about $55,000. Woodline Partners LP raised its position in shares of Kymera Therapeutics by 2.3% in the 4th quarter. Woodline Partners LP now owns 537,428 shares of the company’s stock worth $21,621,000 after acquiring an additional 12,334 shares in the last quarter. Vident Advisory LLC bought a new position in shares of Kymera Therapeutics in the 4th quarter worth about $236,000. Finally, State of Wyoming acquired a new stake in shares of Kymera Therapeutics in the 4th quarter valued at about $45,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.